Related resources
Full-text held externally
- PMID: 23437792
- UKPMCID: 23437792
- DOI: 10.1111/jdv.12118
Search for item elsewhere
University researcher(s)
Academic department(s)
A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.
Mrowietz, U; de Jong, E M G J; Kragballe, K; Langley, R; Nast, A; Puig, L; Reich, K; Schmitt, J; Warren, R B
Journal of the European Academy of Dermatology and Venereology : JEADV. 2014;28(4):438-53.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 23437792
- UKPMCID: 23437792
- DOI: 10.1111/jdv.12118
Abstract
BACKGROUND: There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice. OBJECTIVE: To provide practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis. METHODS: Dermatologists from 33 countries contributed to the Transitioning Therapies programme. Fourteen questions were identified. Answers were drafted based on systematic literature reviews (7/14 questions) and expert opinion (7/14 questions). Using a modified Delphi procedure, dermatologists from 30 countries voted on their level of agreement with each draft answer (scale: 1-9, strong disagreement to strong agreement). Consensus was defined as ≥75% of participants scoring within the 7-9 range. RESULTS: Consensus was achieved on the answers to all questions. Recommendations for the use of cyclosporine and methotrexate were agreed. Transitioning from a conventional systemic therapy to a biological agent may be done directly or with an overlap (if transitioning is required because of lack of efficacy) or potentially with a treatment-free interval (if transitioning is required for safety reasons). Combination therapy may be beneficial. Continuous therapy for patients on biologicals is strongly recommended. However, during successful maintenance with biological monotherapy, a dosage reduction may be considered to limit drug exposure, although this may carry the risk of decreased efficacy. Switching biologicals for reasons of efficacy should be done without a washout period, but switching for reasons of safety may require a treatment-free interval. CONCLUSION: This consensus provides practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis, based on literature reviews and the expert opinion of dermatologists from across the globe.